Close
FSLY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fastly, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Jun 1, 2024 08:15AM

SAN DIEGO, June 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fastly, Inc. (NYSE: FSLY) securities between February 15, 2024 and May 1, 2024, both dates inclusive (the “Class Period”), have until July 23, 2024 to seek appointment as lead plaintiff of the Fastly class action lawsuit. Captioned Kula v. Fastly, Inc., No. 24-cv-03170 (N.D. Cal.), the Fastly class action lawsuit charges Fastly and certain of... (continue reading...)


Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Jun 1, 2024 08:15AM

 

NON-REGULATORY PRESS RELEASE

Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website:... (continue reading...)


Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting Jun 1, 2024 08:15AM

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31... (continue reading...)


Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Jun 1, 2024 08:10AM

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study

Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years

TRUST-I is one of two registrational Phase 2 studies evaluating taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC

NEW YORK--(BUSINESS... (continue reading...)


Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 Jun 1, 2024 08:05AM

Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors

With approximately two years of median follow-up, as of July 28, 2023, median duration of response (DOR) increased by two months from initial analysis to 14.9 months

DUBLIN, June 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced... (continue reading...)


More Press Releases

View Older Stories

Jun 1, 2024 08:05AM Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
Jun 1, 2024 08:00AM Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Jun 1, 2024 08:00AM Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
Jun 1, 2024 08:00AM James Avery Artisan Jewelry Opens New Store at Westover Marketplace
Jun 1, 2024 08:00AM Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Jun 1, 2024 08:00AM TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Jun 1, 2024 08:00AM Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Jun 1, 2024 08:00AM Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Jun 1, 2024 08:00AM Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Jun 1, 2024 08:00AM BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
Jun 1, 2024 08:00AM Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
Jun 1, 2024 08:00AM KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
Jun 1, 2024 08:00AM Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
Jun 1, 2024 08:00AM OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
Jun 1, 2024 08:00AM Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Jun 1, 2024 08:00AM Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
Jun 1, 2024 08:00AM Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Jun 1, 2024 08:00AM CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
Jun 1, 2024 08:00AM Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Jun 1, 2024 08:00AM Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Jun 1, 2024 07:55AM ENPH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Enphase Energy, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jun 1, 2024 08:15AM Gruvtype features de Buyer Products in Global Culinary Adventure with Free "Street, Beach & Sky" Preview Cookbook
Jun 1, 2024 07:10AM Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemo
Jun 1, 2024 07:00AM Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Jun 1, 2024 07:38AM Horizon Wealth Donates $3 Million for Brazil's Post-Disaster Reconstruction
Jun 1, 2024 07:38AM Eurasian Capital Participates in the Third ICPAC Mediterranean Financial Summit: Exploring the Future Frontiers of Finance
Jun 1, 2024 06:20AM XAR and Salus Join Forces to Build zkLogin 'Hikari': The Final Step to Mass Adoption on Starknet
Jun 1, 2024 07:05AM Brandmydispo Continues to Innovate the Custom Mylar Bag Space
Jun 1, 2024 05:55AM ZEEKR Announces May 2024 Delivery Update
Jun 1, 2024 06:43AM Pamela Dowell's newly released "Saucey's Adventure" is a delightful adventure of a young unicorn in an unknown land.
Jun 1, 2024 05:42AM VENTYX SHAREHOLDER REMINDER: BFA Law Reminds Ventyx Biosciences, Inc. (NASDAQ: VTYX) Shareholders to Contact the Firm About Ongoing Investigation
Jun 1, 2024 05:41AM SQSP (NYSE) REMINDER: BFA Law Reminds Squarespace Shareholders to Inquire About Ongoing Investigation into the $44 Buyout Offer
Jun 1, 2024 05:39AM SPT (NYSE) FRAUD ALERT: Sprout Social, Inc. Investors who Lost Money when Stock Plummeted 40% are Encouraged to Contact BFA Law about Upcoming Deadline
Jun 1, 2024 05:37AM PATH (NYSE) INVESTOR ALERT: UiPath, Inc. Investigated for Securities Fraud After 34% Stock Drop, Contact BFA Law if You Suffered Losses
Jun 1, 2024 05:36AM CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer
Jun 1, 2024 05:34AM CAE (NYSE) INVESTOR ALERT: CAE, Inc. Investigated for Securities Fraud from Impairment Charges, Contact BFA Law if You Suffered Losses
Jun 1, 2024 05:33AM BIIB (NASDAQ) FRAUD ALERT: Biogen Inc. Investors who Lost Money are Encouraged to Contact BFA Law about Upcoming Legal Deadline
Jun 1, 2024 05:30AM NIO Inc. Provides May 2024 Delivery Update
Jun 1, 2024 05:00AM XPENG Announces Vehicle Delivery Results for May 2024
Jun 1, 2024 03:23AM Subsea7 awarded four PLSV contracts in Brazil
Jun 1, 2024 03:00AM Swiss Properties Invest has finalised the acquisition of an attractive commercial property in Koblenz in the Canton of Aargau
Jun 1, 2024 02:43AM Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
Jun 1, 2024 02:28AM ALL-TIME BEST MONTHLY SALES FOR THE KIA EV9 AND SPORTAGE SUVs LEAD KIA AMERICA TO SECOND BEST SALES MONTH IN COMPANY HISTORY IN MAY
Jun 1, 2024 02:00AM 'A Fu, the hutong gentleman'
Jun 1, 2024 01:46AM HTX Ventures Invests in Babylon to Advance Trustless Bitcoin Staking
Jun 1, 2024 12:30AM Pink Curing Salt: SPQR Seasonings Becomes Best-Selling #1 Brand On Amazon.com
Jun 1, 2024 12:27AM VTRConnect Launches Real Estate Mega App
Jun 1, 2024 12:00AM Flash News: OKX Lists WLD/USDC Spot Trading Pair
May 31, 2024 11:13PM AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
May 31, 2024 10:06PM Unigold Announces Extension of Non-Brokered Private Placement of up to $2,000,000
View Older Stories